Revolution Medicines was “the talk of the town” at AACR this week, as STAT put it, and yesterday’s data explained why. The combination of daraxonrasib plus standard chemotherapy (gemcitabine/nab-paclitaxel) delivered a 58% confirmed overall response rate in previously untreated metastatic pancreatic cancer—more than doubling historical chemotherapy response rates of approximately 23% in this setting. Daraxonrasib monotherapy in the same population hit 47%. Six-month progression-free survival was 84% for the combination and 71% for monotherapy. Median PFS and OS were not yet mature at data cutoff, meaning patients are still alive and progressing slowly enough that the curves have not crossed the median threshold. But the real surprise was not the combination data. It was RM-055—an entirely new class of compound that Revolution unveiled at the meeting. RM-055 is a catalytic RAS(ON) inhibitor that does not just block RAS signaling but actively converts mutant RAS back to its inactive state. In preclinical models, RM-055 overcame resistance to existing RAS inhibitors, addressing the single biggest limitation of current targeted therapies. Revolution also announced that full Phase 3 RASolute 302 data will be presented in a plenary session at the ASCO Annual Meeting on May 31—the most prestigious slot at the world’s largest oncology meeting. And daraxonrasib has received Breakthrough Therapy Designation from the FDA.
Top Story: Daraxonrasib Delivers 58% Response Rate in First-Line Pancreatic Cancer at AACR
What Happened: Revolution Medicines presented updated Phase 1/2 data from two trials of daraxonrasib in previously untreated metastatic pancreatic cancer at AACR 2026 on April 21.
The Combination Data: Daraxonrasib Plus Chemotherapy
From the RMC-GI-102 trial (Abstract LB407): 40 patients with previously untreated RAS-mutant metastatic PDAC received daraxonrasib 200mg once daily plus gemcitabine/nab-paclitaxel on a Day 1 and Day 15 schedule. Data cutoff was December 1, 2025.
The results: a confirmed overall response rate of 58% and a six-month PFS estimate of 84%. The safety profile was manageable and consistent with the known profiles of each agent individually. Median PFS and OS were not yet mature at data cutoff.
The Monotherapy Data: Daraxonrasib Alone in Untreated Patients
From the RMC-6236-001 trial (Abstract LB337): 40 patients with previously untreated RAS-mutant metastatic PDAC received daraxonrasib 300mg daily as monotherapy.
The results: an overall response rate of 47% and a six-month PFS estimate of 71%. All-grade treatment-related adverse events occurred in 95% of patients. Grade 3 or higher TRAEs occurred in 38%, with rash, diarrhea, and stomatitis as the most common. No Grade 4 or 5 TRAEs were reported. The safety profile was consistent with the second-line daraxonrasib data from RASolute 302.
What the Numbers Mean in Historical Context
The combination response rate needs to be understood against what chemotherapy alone delivers in first-line metastatic pancreatic cancer. Gemcitabine/nab-paclitaxel—the chemotherapy backbone used in the combination arm—historically produces response rates of approximately 23% in this setting.
Daraxonrasib plus GnP at 58% ORR is more than 2.5 times the historical GnP response rate. The six-month PFS of 84% is equally striking—in the pivotal trial that established GnP as standard of care, six-month PFS was substantially lower.
These are Phase 1/2 data in 40 patients with immature survival endpoints, so appropriate caution is warranted. Small sample sizes can produce response rates that do not fully replicate in larger registrational studies, and early-phase trial populations may not perfectly represent the real-world patient mix. But the consistency across the dataset is compelling: monotherapy at 47%, combination at 58%, and the Phase 3 RASolute 302 monotherapy data in second-line at the HR 0.40 survival benefit reported two weeks ago. The picture is coherent. Daraxonrasib works in pancreatic cancer across lines of therapy and treatment approaches.
These Data Validate the RASolute 303 Phase 3 Design
The combination results directly support the design of the Phase 3 RASolute 303 trial, which began dosing on April 2 and is evaluating daraxonrasib both as monotherapy and in combination in first-line metastatic PDAC. The Phase 1/2 combination data demonstrates that the 58% response rate and 84% six-month PFS are achievable in this population, giving the Phase 3 trial a strong clinical foundation.
If RASolute 303 confirms the Phase 1/2 signal in a larger randomized population, Revolution would have registrational-quality data covering both first-line and second-line pancreatic cancer—spanning the entire treatment continuum with a single platform.
Our Pro brief analyzes what 58% ORR and 84% six-month PFS mean for the RASolute 303 Phase 3 design, how the combination data changes peak sales estimates, and how the first-line opportunity roughly doubles the addressable patient population. [Details below.]
RM-055: Revolution Unveils a Next-Generation Compound That Overcomes Resistance
What Happened: Revolution presented preclinical data on RM-055 (Abstract 6782), a novel catalytic RAS(ON) inhibitor representing an entirely new class of compound in the RAS-targeted oncology space.
The Mechanism: Converting Mutant RAS Back to Its Inactive State
Every targeted therapy eventually faces resistance. Tumors adapt by activating alternative signaling pathways, acquiring secondary mutations, or altering expression levels. In the RAS inhibitor field, emergent resistance has already been observed with first-generation KRAS G12C inhibitors in lung cancer. This is the single biggest challenge facing the entire class.
RM-055 addresses this problem through a fundamentally different mechanism than existing RAS inhibitors. Instead of blocking RAS signaling—which RAS-addicted tumors can work around through adaptive mechanisms—RM-055 catalytically converts mutant RAS from its active (ON) state back to its inactive (OFF) state. It accelerates the GTP-to-GDP hydrolysis reaction that mutant RAS proteins cannot perform on their own, mimicking how normal RAS is regulated in healthy cells.
CEO Mark Goldsmith called RM-055 “a novel class.” Chief Scientific Officer Jan Smith said the catalytic inhibitors address “emergent resistance to RAS inhibitors,” which has been a long-sought goal of the RAS research community for years.
The Preclinical Data
In preclinical models, RM-055 drove deep, durable tumor regressions across KRAS G12 mutant pancreatic, non-small cell lung cancer, and colorectal xenograft models. Critically, the compound showed activity in tumors that had escaped prior RAS inhibitors—directly demonstrating its ability to overcome resistance. RM-055 also preferentially suppressed mutant tumors versus normal tissues, suggesting a therapeutic window that could translate to manageable side effects in the clinic.
Why RM-055 Matters for the Franchise
If RM-055 translates from preclinical models to clinical activity, Revolution would have a built-in franchise sequence: daraxonrasib as the first-line RAS inhibitor, followed by RM-055 (or the combination) for patients who develop resistance. That is a therapeutic franchise with a next-generation defense already in development.
The RAS research community has been pursuing catalytic approaches to restore normal RAS regulation for years. Revolution appears to be the first company to demonstrate that catalytic conversion of mutant RAS works in preclinical tumor models with the efficacy and selectivity needed to support clinical development.
Revolution has not disclosed a specific IND filing timeline for RM-055.
Our Pro brief analyzes why catalytic RAS inhibitors could be the most important preclinical data at AACR 2026, how the resistance-overcoming mechanism addresses the central limitation of current targeted therapies, and what RM-055 adds to the franchise value model. [Details below.]
ASCO Plenary Slot Secured for May 31
Revolution announced that detailed Phase 3 RASolute 302 results will be presented in a plenary session at the ASCO Annual Meeting on May 31 in Chicago. Brian Wolpin, MD, MPH, of the Dana-Farber Cancer Institute and principal investigator for the trial, will present.
Why the Plenary Matters: The ASCO plenary is the most prominent presentation slot at the world’s largest oncology meeting, reserved for the most practice-changing data of the year. Securing this slot is a peer-reviewed validation by the ASCO scientific committee that the RASolute 302 results meet the highest threshold of clinical importance. The presentation will include detailed subgroup analyses, progression-free survival data (not yet publicly disclosed from RASolute 302), mature survival curves, and comprehensive safety data.
The subgroup analyses will be particularly important for understanding which patient populations benefit most—whether the survival advantage is consistent across KRAS mutation subtypes, age groups, geographic regions, and lines of prior therapy. PFS data will add a second efficacy dimension to the overall survival results already reported. For payers and formulary committees, the totality of the ASCO presentation will inform pricing and access decisions.
The May 31 plenary will be the most important single event for Revolution Medicines this year. It is where the RASolute 302 data goes from a topline readout to a fully characterized dataset that regulators, clinicians, and payers will use to evaluate daraxonrasib’s place in pancreatic cancer treatment. Between now and May 31, the data will be discussed in abstract terms. After May 31, the conversation shifts to specifics: label scope, regulatory filing timeline, and commercial launch preparation.
Corporate Update: Offerings Close at $2.2B
Revolution announced on April 17 that its concurrent public offerings closed at approximately $2.2 billion in aggregate gross proceeds after underwriters exercised the full option to purchase additional shares. This is up from the previously reported $2 billion ($1.5 billion in stock plus $500 million in convertible notes). The additional approximately $200 million came from the underwriter option on common stock.
Combined with pre-existing cash, Revolution now has total liquidity well in excess of $4 billion—sufficient to fund multiple registrational trials, the CNPV NDA filing, and pre-launch commercialization infrastructure without requiring additional capital raises.
Breakthrough Therapy Designation Granted
The FDA has granted Breakthrough Therapy Designation for daraxonrasib in pancreatic cancer. The designation provides intensive FDA guidance on efficient drug development, rolling review eligibility, and organizational commitment from senior FDA leadership. Combined with Revolution’s stated intention to file under the CNPV program, the BTD creates a regulatory pathway designed for accelerated review.
The combination of Phase 3 overall survival data (HR 0.40), Breakthrough Therapy Designation, Orphan Drug Designation (granted October 2025), and the CNPV filing intention creates one of the most streamlined regulatory pathways for any oncology drug currently in development.
Strategic Themes
1. The First-Line Combination Data Roughly Doubles the Commercial Opportunity
The Phase 3 RASolute 302 data established daraxonrasib in second-line pancreatic cancer. Yesterday’s AACR data opens first-line. The addressable patient population in first-line metastatic PDAC is substantially larger than second-line because it captures patients at the beginning of their disease journey, when they are most numerous and healthiest. If the RASolute 303 Phase 3 trial confirms the 58% combination ORR and 84% six-month PFS signal in a larger randomized population, the commercial opportunity expands dramatically beyond what current analyst peak sales estimates reflect.
2. RM-055 Gives Revolution a Next-Generation Franchise Behind Daraxonrasib
The catalytic RAS(ON) mechanism is not just a backup compound—it is a conceptual breakthrough in how RAS-driven cancers can be treated. If RM-055 works clinically, Revolution has a therapeutic sequence that addresses the resistance problem that eventually limits every targeted therapy. First daraxonrasib, then RM-055 when resistance emerges. That sequence creates a franchise with built-in longevity that single-agent programs cannot match, because it anticipates and addresses the biological mechanism by which tumors will escape the initial therapy.
3. The ASCO Plenary Is the Validation Event
Securing the ASCO plenary slot is the scientific community’s validation that the RASolute 302 data is practice-changing. The May 31 presentation will be the event where the full dataset—subgroup analyses, PFS data, mature survival curves, detailed safety—becomes available for comprehensive clinical and regulatory evaluation. Between now and May 31, the data will be discussed in abstract terms. After May 31, the conversation shifts to specifics: label scope, regulatory filing timeline, and commercial launch preparation.
4. Revolution’s Pipeline Depth Is Becoming Its Most Underappreciated Asset
Daraxonrasib in second-line PDAC (Phase 3 positive). Daraxonrasib in first-line PDAC (Phase 1/2 combination data strong, Phase 3 enrolling). Zoldonrasib in NSCLC (Phase 1 data presented at AACR plenary). RM-055 as a next-generation catalytic inhibitor (preclinical). The BMS navlimetostat combination. Four registrational studies. The company that two months ago was a clinical-stage biotech with a single Phase 3 readout is rapidly becoming a multi-asset oncology platform with franchise depth across indications, lines of therapy, and next-generation mechanisms.
Frequently Asked Questions
What did the daraxonrasib combination data show in first-line pancreatic cancer?
In 40 previously untreated patients with RAS-mutant metastatic PDAC, daraxonrasib 200mg daily plus gemcitabine/nab-paclitaxel achieved a confirmed 58% overall response rate and an 84% six-month PFS estimate. Historical GnP response rates are approximately 23%. Median PFS and OS were not yet mature at the December 2025 data cutoff. The safety profile was manageable and consistent with each agent individually.
How did the monotherapy data compare?
Daraxonrasib 300mg daily as monotherapy in 40 untreated patients achieved a 47% ORR and 71% six-month PFS. Grade 3 or higher treatment-related adverse events occurred in 38% of patients, with rash, diarrhea, and stomatitis most common. No Grade 4 or 5 TRAEs were reported.
What is RM-055?
A novel catalytic RAS(ON) inhibitor that converts mutant RAS from its active (ON) state back to its inactive (OFF) state—a fundamentally different mechanism than current RAS inhibitors that block signaling. In preclinical models, RM-055 drove deep, durable tumor regressions across pancreatic, NSCLC, and colorectal xenografts, including tumors that had escaped prior RAS inhibitors. CEO Mark Goldsmith called it “a novel class.”
Why does overcoming RAS inhibitor resistance matter?
Every targeted therapy eventually faces resistance as tumors adapt. Emergent resistance has already been observed with first-generation KRAS inhibitors. If RM-055 translates clinically, Revolution would have a therapeutic sequence: daraxonrasib first, then RM-055 for patients who develop resistance. That built-in next line of defense is what separates a single product from a durable franchise.
What is the ASCO plenary presentation?
Full Phase 3 RASolute 302 data will be presented on May 31 in Chicago by Brian Wolpin of Dana-Farber Cancer Institute. The plenary is the most prestigious slot at the world’s largest oncology meeting. Expect detailed subgroup analyses, PFS data (not yet publicly disclosed), mature survival curves, and comprehensive safety data. This is the definitive data presentation for the daraxonrasib regulatory filing.
Has Revolution received Breakthrough Therapy Designation?
Yes. The FDA granted Breakthrough Therapy Designation for daraxonrasib in pancreatic cancer, providing intensive FDA guidance, rolling review eligibility, and senior leadership commitment. Combined with Orphan Drug Designation (October 2025) and the planned CNPV filing, this creates one of the most streamlined regulatory pathways for any oncology drug in development.
How much did Revolution raise in total?
Approximately $2.2 billion in aggregate gross proceeds after underwriters exercised the full option to purchase additional shares. The total includes approximately $1.7 billion in common stock and $500 million in convertible notes. Combined with pre-existing cash, Revolution has well over $4 billion in total liquidity.
What does the AACR data mean for the RASolute 303 Phase 3 trial?
The first-line combination data (58% ORR, 84% six-month PFS) directly validates the design of RASolute 303, which began dosing April 2 and evaluates daraxonrasib both as monotherapy and in combination in first-line metastatic PDAC. If the Phase 3 confirms the Phase 1/2 signal, Revolution would have registrational data covering both first-line and second-line pancreatic cancer.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
First-Line Combo Math: What 58% ORR Changes. We model what the combination data means for the RASolute 303 Phase 3 design, how adding first-line to the commercial model changes peak sales estimates, and how the immature survival endpoints position for the final readout.
RM-055 and the Resistance Problem. We analyze why catalytic RAS(ON) inhibitors could be the most important preclinical data at AACR 2026, how the mechanism works at the molecular level, and what the resistance-overcoming activity means for Revolution’s franchise longevity.
AACR 2026 Scoreboard: The Complete Recap. We rank the five most important oncology data sets from the meeting, assess the competitive implications for ADC developers, and frame the narrative heading into ASCO on May 31.
Plus: ASCO plenary preview, Breakthrough Therapy Designation regulatory implications, $2.2B capital position analysis, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
